Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211 At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response
Molecular Pharmaceutics · 06.11.2023 · 20 (11) · 5543-5553
DOI: 10.1021/acs.molpharmaceut.3c00427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 03.10.2023. Verfasst von Shanshan Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Anti-Cancer Association.
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy. Due to limited treatment options, patients with SCLC have a poor prognosis. We have found, however, that intravenously administered octreotide (Oct) armed with astatine-211 ([211At]SAB-Oct) is effective against a somatostatin receptor 2 (SSTR2)-positive SCLC tumor in SCLC tumor-bearing BALB/c nude mice. In biodistribution analysis, [211At]SAB-Oct achieved the highest concentration in the SCLC tumors up to 3 h after injection as time proceeded. A single intravenous injection of [211At]SAB-Oct (370 kBq) was sufficient to suppress SSTR2-positive SCLC tumor growth in treated mice by inducing DNA double-strand breaks. Additionally, a multitreatment course (370 kBq followed by twice doses of 370 kBq for a total of 1110 kBq) inhibited the growth of the tumor compared to the untreated control group without significant off-target toxicity. Surprisingly, we found that [211At]SAB-Oct could up-regulate the expressions of calreticulin and major histocompatibility complex I (MHC-I) on the tumor cell membrane surface, suggesting that α-particle internal irradiation may activate an endogenous antitumor immune response through the regulation of immune cells in the tumor microenvironment, which could synergically enhance the efficacy of immunotherapy. We conclude that [211At]SAB-Oct is a potential new therapeutic option for SSTR2-positive SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China.
- Institute of Nuclear Medicine, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China.
- Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, People's Republic of China.
ORCID-Profile: Fei Yu
Förderung
- National Natural Science Foundation of China
- Shanghai Anti-Cancer Association
Zitieren
APA
Qin, S., Yang, Y., Zhang, J., Yin, Y., Liu, W., Zhang, H., Fan, X., Yang, M., & Yu, F. (2023). Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211 At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response. Molecular Pharmaceutics, 20(11), 5543-5553. https://doi.org/10.1021/acs.molpharmaceut.3c00427
Vancouver
Qin S, Yang Y, Zhang J, Yin Y, Liu W, Zhang H, et al. Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211 At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response. Molecular Pharmaceutics. 2023;20(11):5543-5553. doi:10.1021/acs.molpharmaceut.3c00427
BibTeX
@article{Qin2023,
author = {Qin, Shanshan and Yang, Yuanyou and Zhang, Jiajia and Yin, Yuzhen and Liu, Weihao and Zhang, Han and Fan, Xin and Yang, Mengdie and Yu, Fei},
title = {Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211 At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response},
journal = {Molecular Pharmaceutics},
year = {2023},
volume = {20},
number = {11},
pages = {5543--5553},
doi = {10.1021/acs.molpharmaceut.3c00427}
}
EUVIMED